Asthma, the prototypic type 2 inflammatory disorder of the lung, is an emergent disease worldwide (Asher et al., 2006; Kim et al., 2010) . Several studies have demonstrated that vascular endothelial growth factor (VEGF) and endo thelial signaling play critical roles in the lung Th2 inflammation (Hoshino et al., 2001a,b; Lee et al., 2004; Simcock et al., 2007; Tuder and Yun, 2008; Asosingh and Erzurum, 2009) . Most prominent were studies demonstrating that trans genic expression of VEGF in the lung leads to eosinophilrich inflammation, mucus metapla sia, and airway remodeling and that selective VEGF receptor 2 (VEGFR2) blockade abrogates aeroallergeninduced pulmonary inflammation . However, the mechanisms of VEGF contribution to this inflammatory cas cade are poorly understood (Voelkel et al., 2006; Tuder and Yun, 2008) .
MicroRNAs (miRNAs) regulate gene ex pression by base pairing with conserved sites within the 3 untranslated region (UTR) of their target mRNAs (Bartel, 2009) . Each miRNA can potentially bind to hundreds of mRNAs in the cell and thus regulate a multitude of functional and structural changes in a cell and organspecific manner (Giraldez et al., 2005; Chen and Rajewsky, 2006; Sokol et al., 2008) . Although the mechanisms of translational regulation by miRNAs have not been fully defined, it is known that miRNAs function through formation of a ribonucleoprotein com plex called the miRNAinduced silencing com plex (miRISC). miRISC contains a guide miRNA bound to one of four mammalian Argonaute proteins and is one of the effector arms of the RNA interference pathway causing mRNA deadenylation and decay or inhibition of translation (Jackson and Standart, 2007) . Of these, Argonaute 2 (Ago2) is the most abun dantly expressed Argonaute in mammalian tissues
RESULTS

VEGF down-regulates lung endothelial miR-1 in Th2 inflammation
To define the relationships between VEGF and miRNA, we evaluated the expression of miRNAs in VEGF transgenic mice and models of Th2 inflammation. Microarray analysis and TaqMan stem loop quantitative RTPCR (qRTPCR) showed that in the lungs of CC10rtTAVEGF 165 trans genic mice, the levels of miR1 were decreased by 50-60% (Fig. 1, a and b) . A comparison of miR1 levels in isolated endothelial (CD31 + , CD45  ) and hematopoietic (CD45 + ) cells from these lungs showed that, in contrast to hematopoietic cells, the levels of miR1 in endothelial cells were diminished by >90% (Fig. 1 c) . In accord with these findings, recombinant VEGF decreased the levels of miR-1 in primary mouse lung endothelial cells (MLECs) cultured in vitro in a concentrationdependent manner (Fig. 1 d) . This downregulation was at least partially MLEC specific because VEGF did not decrease the levels of miR1 in mouse pulmonary artery smooth muscle cells (PASMCs) or a lung epithelial cell line (MLE12; Fig. 1 e) .
To test the Th2 relevance of this downregulation, we next analyzed the expression of miR1 in two well established models of lung Th2 inflammation. Similar to VEGF transgenic mice, overexpression of IL13 in the lung epithelium inhib ited expression of miR1 (Fig. 2 a) , and this inhibition was more prominent in endothelial cells (Fig. 2 b) . To investi gate the consistency of this downregulation in aeroallergen induced Th2 inflammation and show the role of VEGF, we (Wang et al., 2012) and is the only mammalian Argonaute with endonucleolytic activity (Liu et al., 2004) . Recent stud ies have demonstrated that miRNAs play important roles in a wide variety of biological processes (Giraldez et al., 2005; Chen and Rajewsky, 2006; Sokol et al., 2008; Fish et al., 2008; Wang et al., 2008; Suárez et al., 2008; Bonauer et al., 2009; Nicoli et al., 2010) . However, the roles of miRNA in Th2 inflammation and the inflammatory effects of VEGF have not been investigated.
We hypothesized that the effects of VEGF in Th2 inflam mation are mediated by its ability to alter endothelial miRNA and their downstream targets. To test this hypothesis, we eval uated the miRNA and miRNA target alterations in VEGF transgenic mice and models of aeroallergeninduced Th2 inflammation. We found that lungtargeted VEGF down regulated miR1, most prominently in the endothelium, and that a similar downregulation takes place in lungtargeted IL13 transgenic and aeroallergensensitized and challenged mice. We next demonstrated that intranasal delivery of miR1 decreased Th2 and IL13-stimulated inflammation and that antagonizing miR1 rescued Th2 immunity in the context of VEGFR2 blockade. We also found a direct target of miR1, Mpl, and defined the critical role of Mpl in Th2 inflammation by silencing this gene in Th2inflamed lungs. Lastly, we showed that Mpl, similar to its role in platelets, regulates the expression of Pselectin in the lung endo thelium. Overall, these experiments define a novel VEGF driven, miR1-Mpl-Pselectin effector pathway in lung Th2 inflammation. (a) VEGF was overexpressed in the lung epithelium of CC10-rtTA-VEGF transgenic mice. RNA from the lungs of these mice (VEGFtg) and their WT litters was analyzed by microarray. miRNAs that were changed significantly are indicated (n = 3 in each group; P < 0.01). Blue indicates P > 0.01, and red indicates P < 0.01. (b) Relative expression of miR-1 in these lungs was measured by TaqMan qRT-PCR (values normalized to WT; two experiments; n = 5 in each group; *, P < 0.04). (c) Relative expression of miR-1 was measured by TaqMan qRT-PCR in lung endothelial (CD31 + , CD45  ) or hematopoietic (CD45 + ) cells isolated from these lungs (values normalized to WT; three experiments; n = 3-4 per group; *, P < 0.05). (d) Recombinant VEGF was added to MLECs in culture, and relative expression of miR-1 was measured by TaqMan qRT-PCR (values normalized to PBStreated group; two experiments; n = 4 in each group; *, P < 0.05). (e) Recombinant VEGF was added to MLECs, lung epithelial cells (MLE12), and PASMCs, and relative expression of miR-1 was measured as in a (values normalized to the corresponding PBS-treated group; three experiments; n = 4 in each group; *, P < 0.05). All error bars represent mean ± SEM.
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of these Th2 hallmark responses (Fig. 3, a-d ). These changes were accompanied by a significant decrease in mucus (MUC5) hypersecretion and lung tissue eosinophilia, further demon strating that miR1 inhibitory effects are not limited to BAL (Fig. 3 e) . In agreement with the above experiments, the se cretion of eotaxin and the accumulation of pulmonary CD4 + T cells were also significantly inhibited, whereas the level of VEGF in the BAL remained unchanged (Fig. 3 f) , suggest ing that the delivered miR1 is not directly targeting VEGF. Levels of serum OVAspecific IgE also did not differ among different OVAchallenged groups (not depicted), suggesting that, as expected, miR1 delivery at the time of the antigenic challenge does not affect T cell sensitization. In accord with these observations, miR1 delivery also ameliorated ongoing Th2 inflammation. As shown in Fig. 3 g, the effectiveness of intranasal miR1 was not limited to its prophylactic adminis tration and intranasal delivery even 24 h after the first anti genic challenge inhibited the BAL eosinophilia, IL13, and eotaxin secretion.
To further investigate the roles of miR1 in Th2 inflam mation, we also characterized the effects of miR1 blockade. As can be seen in Fig. 4 a, the intranasal administration of an miR1 antagomir reversed the inhibitory effects of VEGFR blockade and rescued OVAinduced eosinophilic inflamma tion, mucus metaplasia, and IL5 secretion. Collectively, these observations demonstrate that miR1 downregulation plays a critical role in many facets of pulmonary Th2 inflammation. measured the level of miR1 in lung endothelium of OVA sensitized and challenged mice treated with intranasal or systemic VEGFR2 blockers. We first showed that intra nasal delivery of VEGFR2 siRNA decreased expression of VEGFR2 in the lung endothelium by >70% (Fig. 2 c) . As shown in Fig. 2 (d and e) , OVA sensitization and challenge reduced the expression of endothelial miR1 by >70% and VEGFR2 blockade in the lung (by intranasal delivery; Fig. 2 
miR-1 controls Th2 inflammation in the lung
To further define the roles of miR1 in Th2 inflammation, we evaluated the effects of miR1 delivery in the OVA model. A doublestranded miR1 mimic or its negative control (scr-miR1) were delivered intranasally to mice at the time of OVA challenge. Using this method, miR1 levels increased by >10fold in the lung endothelium, confirming the effi ciency of delivery (Fig. 3 a) . In these experiments, mice that received the vehicle or scrambled miR1 control manifested significant increases in tissue inflammation, eosinophilia, and type 2 cytokine accumulation in the bronchoalveolar lavage fluid (BAL) and airway hyperresponsiveness (AHR) in re sponse to methacholine challenge (Fig. 3, a-d) . However, miR1 delivery at the time of OVA challenge ameliorated each (a) IL-13 expression was induced in the lung epithelium of CC10-rtTA-Il-13 transgenic mice for 7 d, and miR-1 expression was measured by TaqMan qRT-PCR in the whole lung RNA from these mice and their WT litters (values normalized to WT; three experiments; n = 3 or more in each group; *, P < 0.0001). (b) Relative expression of miR-1 was measured in endothelial cells isolated from these lungs (two experiments; n = 3 or 4 mice in each group; *, P < 0.04). (c) C57BL/6 mice were sensitized with OVA and challenged for 3 d, 3 wk after the sensitization. Intranasal VEGFR2 siRNA (VR2si) or scrambled control (scr-ctrl) was delivered every day before the OVA challenge. Lung endothelial cells were isolated after the last challenge, and the level of VEGFR2 mRNA was measured by real-time qRT-PCR (two experiments; n = 4 or more in each group; *, P < 0.02). (d) Relative expression of miR-1 was measured by TaqMan qRT-PCR in the endothelial cells isolated from mice treated as described in c (values are normalized to PBSchallenged control group; two experiments; n = 4 or more in each group; VR2si group compared with both OVA and scr-ctrl groups: *, P < 0.05). (e) C57BL/6 mice were sensitized and challenged with OVA as described in c and received i.p. SU5416 or vehicle (DMSO) the day before the first challenge and every day afterward. Expression of miR-1 was measured by TaqMan qRT-PCR in lung endothelial cells (values normalized to vehicle control; two experiments; n = 5 in each group; SU5416 compared with both other groups: *, P < 0.05). Relative expression of miR-1 is measured in all experiments by comparing it with the internal control (sno202) and normalizing to a calibrator (WT or PBS treatment). Error bars represent mean ± SEM. (a) C57BL/6 mice were sensitized and challenged with OVA as described in Fig. 2 c. Intranasal miR-1 or scrambled miR-1 (scr-miR-1) was delivered the day before the first challenge and every day afterward. The level of miR-1 was measured by TaqMan qRT-PCR in lung endothelial cells (normalized to the control group; n = 4 in each group; *, P < 0.05). (b) Lungs from these mice were stained with H&E (top) to show the level of peribronchial inflammation and PAS (bottom) to show the extent of mucus metaplasia (dark red) in the large airways. Bars, 50 µm.
targets, we first asked whether miR1 recruits the corre sponding mRNAs to the RISC. MLECs were transfected with miR1 or scr-miR1, and the cell lysates were immune precipitated with antiAgo2. Recruitment of specific mRNAs to the RISC was assayed by realtime qRTPCR on these immunoprecipitates (IPs). We first confirmed the efficiency of miR1 transfection and its presence in the RISC by measur ing the level of miR1 in the Ago2IP (Fig. 5 b) . The concen trations of seven of the candidate genes (Bxdc2, Ick, Ss18, St5, Smarcb1, Mpl, and Hspd1) and two other putative miR1 tar gets, Ets1 (v-ets erythroblastosis virus E26 oncogene homologue 1) and Endoglin, with known roles in angiogenesis, were com pared in the Ago2IPs from miR1-transfected cells with those of controls. As shown in Fig. 5 c, among all of the genes analyzed, miR1 only recruited Mpl mRNA to the RISC. We further confirmed the miR1-dependent recruitment of Mpl mRNA in the more stringent enrichment assay (Fig. 5 d) . In this assay, the specific recruitment of targets to miRISC is analyzed by measuring the enrichment of mRNAs in the IP compared with the total cytoplasmic (input) fraction. Once again, Mpl mRNA was uniquely enriched in the IP fraction, suggesting that Mpl is a direct target of miR1.
We next examined the validity of these observations in the whole lung and after intranasal miR1 delivery. Lung epi thelial IL13 transgenic mice were treated with intranasal miR1 or scr-miR1, and enrichment of Mpl mRNA and three other putative targets of miR1 (ADAR [adenosine deaminase RNA specific] , Hhip [hedgehog-interacting protein] , and Dhx15 [DEAH box polypeptide 15]) were analyzed as above. As shown in Fig. 5 (e and f), miR1 is enriched in the RISC after intranasal delivery and recruits Mpl and ADAR mRNAs to this compartment. ADAR is a previously described target of miR1 in fibroblasts and cardiac myocytes (Lim et al., 2005; Srivastava, 2006; Vinther et al., 2006) , and enrichment of ADAR in the lung RISC further confirms that miR1 reaches the miRISC upon intranasal delivery.
The VEGF-miR-1 axis regulates Mpl expression in the lung endothelial cells through the direct interaction of miR-1 with the Mpl 3 UTR To validate the aforementioned targeting in a direct study, we first cloned the fulllength Mpl 3 UTR downstream of a miR-1 regulation in other models of type 2 inflammation To determine whether the effects of miR1 were limited to the OVA model or dependent on antigenic sensitization, we tested the effects of miR1 in house dust mite (HDM) and lung IL13 transgenic models, respectively. In keeping with our findings in the OVA model, intranasal delivery of miR1 to HDMsensitized and challenged mice at the time of anti gen challenge significantly decreased eosinophilic inflamma tion and type 2 cytokine and eotaxin elaboration (Fig. 4 b) . As previously reported (Zhu et al., 1999) , overexpression of IL13 in the lung epithelium induces features of Th2 inflam mation such as eosinophilic inflammation and mucus metapla sia without any prior antigenic sensitization or challenge. As shown in Fig. 4 (c and d) , intranasal miR1 inhibited both of these antigenindependent type 2 responses. These experi ments clearly demonstrate that the regulatory effects of miR1 are not OVA specific and can be seen in other aeroallergen induced and antigenindependent inflammatory responses.
Identification of miR-1 targets by expression profiling and RISC analysis
Because of the incomplete base pairing between miRNAs and their targets, identification of genuine miRNA targets is often fraught with difficulties and most of the available pre diction algorithms produce an inordinate number of potential targets for each miRNA. Appreciating these limitations, we chose a twostep strategy to identify a more limited and spe cific number of candidate genes with a higher possibility of genuine targeting. Because miRNAs often lower the levels of their target mRNAs (Lim et al., 2005; Ziegelbauer et al., 2009) , we first used an arraybased expression profiling of lung endothelial cells to identify potential targets of miR1. We screened for genes that were upregulated in response to VEGF and whose upregulation was inhibited by miR1 (i.e., in the miR1-transfected cells). Using three available predic tion algorithms (Targetscan, miRANDA, and Pictar), we then produced a comprehensive list of all possible miR1 targets. A comparison between the genes that passed both of the aforementioned steps (i.e., were differentially regulated by VEGF in the presence of miR1 and were predicted to be a target of miR1 by a prediction algorithm) produced a list of 10 candidates (Fig. 5 a) . To interrogate these potential miR1 (c) BALs were collected from these mice, and cytospin preps were stained with H&E to determine the number of eosinophils (top). Concentrations of IL-13 (middle) and IL-5 (bottom panel) were measured by ELISA (n = 5 in each group; three experiments; miR-1 + OVA groups were compared with the other OVAchallenged groups by one way ANOVA: *, P < 0.01 for eosinophils and IL-13; and *, P < 0.05 for IL-5). (d) Airway responses were measured by forced oscillation technique. Mean airway resistance (R, cmH2O.s/ml) was measured after exposing ventilated mice to increasing concentrations of methacholine (values are derived from two experiments with 5 or more mice per group; total of 11-13 mice per group; miR-1 group was compared with OVA and OVA + scr-miR-1 groups: *, P = 0.05; **, P = 0.03). (e) MUC5AC (top) was measured in the BAL of these mice by slot blot hybridization and normalized to control (PBS challenged) group. Lung eosinophils (bottom) were quantified by staining the lung sections with Congo red and counting the eosinophils in the peribronchial areas (three experiments; n = 5 mice per group; miR-1 group compared with both OVA and OVA + scr-miR-1 groups: *, P < 0.002; **, P < 0.0002). (f) In the BAL of these mice, eotaxin (top) and VEGF (bottom) were measured by ELISA, and CD4 + cells (middle) were quantified by FACS analysis (three experiments; n = 5 mice per group; miR-1-treated group was compared with both OVA and OVA + scr-miR-1 groups: *, P < 0.05; **, P < 0.025). (g) C57BL/6 mice were sensitized and challenged with OVA as described in Fig. 2 c, and intranasal miR-1 or scr-miR-1 was delivered after each challenge. The number of eosinophils (top) and levels of IL-13 and eotaxin (middle and bottom) were measured in the BAL as described in c (three experiments; n = 4 or more per group; miR-1 group compared with OVA and OVA + scr-miR-1 groups: *, P = 0.029; **, P = 0.033; ***, P = 0.0127). Error bars represent mean ± SEM.
(firefly luciferase-Mpl 3 UTR). Stimulation of these cells with VEGF increased and inhibition of VEGF signaling with its specific receptor inhibitor (SU5416) decreased the MplUTRregulated luciferase expression (Fig. 5 i) .
In Th2 inflammation, VEGF controls the expression of Mpl via down-regulation of miR-1
We first examined the effects of allergic airway inflammation on lung Mpl expression and the role of VEGF in this context. OVA sensitization and challenge increased the levels of lung Mpl to four to five times the levels in controls, and VEGF blockade, in this context, decreased this induction by 60% (Fig. 6 a) . Intranasal delivery of miR1 at the time of antigen challenge had a similar effect and decreased the levels of Mpl in the lung by 50% (Fig. 6 b) . To test whether this down regulation occurs in the endothelium, we measured the levels of Mpl mRNA in lung endothelial cells isolated from miR1 firefly luciferase gene and compared the levels of firefly lucif erase expression (relative to the control Renilla luciferase) after cotransfection with miR1 or its negative control. In these experiments, miR1 reduced the level of firefly lucifer ase by >50% (Fig. 5 g ). To further confirm the site of this interaction, we cloned a 50nt piece of the Mpl 3 UTR containing the predicted miR1 target site ( Fig. 5 h, top) into the firefly luciferase vector and showed that, similar to above, cotransfection of this vector with miR1 inhibits the relative expression of firefly luciferase. We then introduced compen satory mutations in this isolated miR1 site so that it matched the negative control (scr-miR1). As expected, miR1 lost its inhibitory effect on this mutated target site and instead scr-miR1, which was complementary to this site, inhibited the luciferase expression (Fig. 5 h) .
To investigate the specific effect of VEGF on Mpl expres sion, we transfected the MLECs with the Mpl reporter vector Intranasal miR-1 antagomir or scrambled control (scr-control) and SU5416 or vehicle (DMSO) were delivered the day before the first challenge and every day afterward. BALs were collected, and eosinophils (*, P < 0.05), MUC5AC (*, P < 0.0001), and lung IL-5 (*, P < 0.002) were measured as described in Fig. 3 (two experiments; n = 5 in each group; OVA-challenged groups were compared using one-way ANOVA, and the p-values were corrected for multiple comparisons). (b) C57BL/6 mice were sensitized with HDM and challenged intranasally for 3 d in the third week after sensitization. Intranasal miR-1 or scr-miR-1 was delivered the day before the first challenge and every day afterward. BALs were collected, and eosinophils (*, P < 0.05), IL-13 (*, P < 0.05), IL-5 (*, P < 0.015), and eotaxin (*, P < 0.0015) were measured as described in Fig. 3 (graphs represent data from three experiments with n = 5 mice per group; miR-1 groups were compared with both scr-miR-1 and vehicle groups). (c and d) IL-13 expression was induced in the lung epithelium of IL-13 transgenic mice (as described in Fig. 2 a) . Intranasal miR-1 was administered the day before starting doxycycline and every other day afterward. After 7 d, BALs were collected, and the number of eosinophils (*, P < 0.04) and MUC5AC relative expression (*, P < 0.01) were measured as described in Fig. 3 (relative expression of MUC5AC was calculated by normalizing MUC5AC levels in each transgenic group to WT litters; three experiments; n = 3 or more in each group; miR-1 group was compared with the other two transgenic groups). Error bars represent mean ± SEM.
Pselectin in the venules was diminished (Fig. 8 h) , showing that this downregulation occurs in the endothelium. In keeping with the known ability of Mpl to regulate platelet Pselectin (Tibbles et al., 2002) and the inhibitory effect of miR1 on Pselectin expression, these experiments strongly suggest that the VEGF-miR1 axis controls the expression of endothelial Pselectin through regulation of Mpl. Importantly, they also suggest that the VEGF-miR1-Mpl axis mediates its effects on lung Th2 inflammation, at least in part, by regulating this critical adhesion molecule.
The VEGF-miR-1-Mpl axis in human endothelium
To investigate the relevance of the VEGF-miR1-Mpl axis in human pathologies, we first determined whether VEGF regu lated the expression of miR1 in human primary endothelial cells (HUVECs). As shown in Fig. 9 a, VEGF downregulated miR1 in human endothelial cells and inhibition of VEGF signaling abrogated this downregulation. We next asked whether miR1 targets Mpl in human primary endothelial cells. As shown in Fig. 9 b, miR1 decreased the expression of Mpl in HUVECs by >50%. Experiments were next under taken to determine whether this inhibitory effect was mediated through the miR1 interaction with Mpl 3 UTR. Because human Mpl (hMpl) 3 UTR is longer than that of the mouse and has two predicted miR1-binding sites that differ from that in the mouse, human 3 UTR was cloned and used in this study. In these experiments, we cotransfected the miR1 mimic with a reporter plasmid containing firefly luciferase cloned upstream from the human fulllength Mpl 3 UTR. As shown in Fig. 9 c, miR1 cotransfection inhibited the expres sion of firefly luciferase (represented as relative luciferase activ ity) by 50%. Thus, these observations demonstrate that the VEGF-miR1-Mpl pathway is active in human cells.
DISCUSSION
The prevalence of asthma has increased considerably in the past three decades (Barnes, 2010; Kim et al., 2010) . However, despite extensive research in this area, diseasemodifying in terventions for asthma are distinctly lacking (Holgate and Polosa, 2008; Barnes, 2010; Akdis, 2012) . VEGF is a multifac eted, highly conserved cytokine with farreaching effects on biological processes, including angiogenesis, carcinogenesis, and inflammation (Ferrara et al., 2003) . We hypothesized that the inflammatory effects of VEGF are mediated, at least in part, through the regulation of an miRNA pathway. Specifically, we hypothesized that VEGFinduced alterations in endo thelial cell miRNA play an important role in the pathogenesis of pulmonary Th2 inflammation. In the present study, we have defined a novel and critical effector pathway in Th2 in flammation in which VEGF inhibits the expression of endo thelial miR1, leading to an accumulation of its direct target, Mpl, and thereby increased expression of Pselectin in the lung endothelium. This pathway controls the accumulation of Th2 effector cells and eosinophils in the lung after antigenic challenge and regulates the major pathophysiological features of pulmonary Th2 responses. These experiments validated the (or control RNA)-treated mice. As shown in Fig. 6 c, endo thelial Mpl mRNA was decreased by 50% after miR1 intra nasal delivery. To confirm the role of the VEGF-miR1 axis in the upregulation of Mpl in Th2 inflammation, we charac terized the effects of miR1 antagomir in this model. Similar to its effects on lung inflammation and Th2 cytokines, an tagonizing miR1 reversed the effect of VEGF blockade on Mpl expression in the OVAsensitized and challenged mice (Fig. 6 d) . In combination, these findings demonstrate that Mpl upregulation in Th2 inflammation is VEGF dependent and mediated by a VEGFinduced decrease in miR1.
Mpl is required for lung Th2 inflammation
To directly examine the role of Mpl, we next tested the effects of intranasal siRNA against Mpl in the Th2 models. The effi ciency of knockdown by this method was confirmed by showing that levels of lung Mpl protein were decreased by >80% after siRNA delivery (not depicted). Mpl knockdown led to a significant reduction in lung inflammation and mucus metaplasia (Fig. 7 a) , BAL eosinophilia and Th2 cytokine se cretion (Fig. 7 b) , and mucin secretion (Fig. 7 c) . Similarly, in IL13 transgenic mice, Mpl knockdown decreased lung eosinophilia and mucin secretion (Fig. 7, d and e ). These findings demonstrate that Mpl plays a critical role in the pathogenesis of Th2 responses in the lung.
The miR-1-Mpl axis controls the expression of P-selectin in lung endothelium At sites of inflammation, endothelial cells facilitate leukocyte entry into tissues via the expression of leukocyte adhesion molecules (Ley et al., 2007) . Thus, we analyzed the effects of miR1 and Mpl on the expression of endothelial adhesion molecules during Th2 inflammation. Evaluations of mRNA expression arrays of MLECs transfected with miR1 (or its negative control) and stimulated with VEGF (Fig. 8 a) demon strated that miR1 specifically and strongly inhibited the ex pression of Pselectin in lung endothelium. Western blot and histological analysis of the OVAsensitized and challenged lungs showed a significant downregulation of Pselectin after miR1 delivery in the whole lung lysate (Fig. 8 b) , which was quite prominent in lung venules (Fig. 8 c) . Finally, measure ment of the Pselectin mRNA level in lung endothelial cells isolated from these mice (Fig. 8 d) confirmed that miR1 delivery decreases the endothelial expression of Pselectin in the OVAsensitized and challenged mice. However, the Pselectin 3 UTR does not contain an miR1-binding site, and Pselectin mRNA is not recruited to the RISC after miR1 transfection (not depicted), suggesting that the inhibi tory effects of miR1 on Pselectin are indirect and mediated through its target, Mpl. In accord with this hypothesis, Mpl knockdown decreased the level of Pselectin mRNA in MLECs (Fig. 8 e) . More importantly, intranasal delivery of Mpl siRNA caused a significant downregulation of Pselectin ex pression in the OVAsensitized and challenged lungs (Fig. 8 f ) . Pselectin mRNA level in endothelial cells isolated from these lungs was significantly decreased (Fig. 8 g) , and expression of Preliminary investigations have implicated miRNAs in Th2 inflammation. These studies defined an miRNA induced by TLR4 in lung epithelium (Mattes et al., 2009) , highlighted upregulation of miR21 by IL13 (Lu et al., 2009) , and dem onstrated that Let7 targets IL13 3 UTR in vitro and possibly in vivo (Polikepahad et al., 2010; Kumar et al., 2011) . How ever, as valuable as these findings have been, they have only addressed isolated steps in the Th2 cascade. By using two lung targeted transgenics and two widely used aeroallergen inflam mation models, we have been able to identify and validate an miRNA pathway downstream from VEGF and VEGFR2 and demonstrate that it plays a critical role in the elicitation of lung Th2 inflammatory responses. We have also highlighted the relationship between the miR1 target, Mpl, and one of its downstream molecules, Pselectin.
There are two interesting endothelialrelated findings in our studies. First, although miR1 was administered via an intranasal route, it readily reached the pulmonary endothe lium. This demonstrates that an intranasal or aerosol route can be used to deliver miRNA to the pulmonary endothelium. Second, our experiments demonstrate that in Th2 inflamma tion, the level of endothelial miR1 is controlled by VEGF signaling and correlates closely with the extent of inflamma tion. We found the strongest downregulatory effect of VEGF in the endothelium, showed that VEGF blockade inhibits the endothelial miR1 downregulation, and found a genuine, biologically valid target of miR1 in the lung endothelial cells. These data strongly suggest that lung endothelium is a critical integration site for antigentriggered pulmonary Th2 responses. This observation is in line with a recent study defining endo thelial cells as central orchestrators of cytokine responses in duced by influenza infection (Teijaro et al., 2011) .
We used four different approaches to identify a target of miR1. First, by combining in silico prediction and differen tial mRNA expression analysis, we narrowed the list of po tential miR1 targets to 10 genes that are induced by VEGF, functionality of this pathway by demonstrating that miR1 is downregulated and Mpl is upregulated during Th2 inflam mation, miR1 supplementation inhibits the Th2 inflamma tion and Mpl expression and antagonizing miR1 rescues both the Th2 inflammation and Mpl expression after VEGF blockade, and finally, Mpl silencing, similar to miR1 delivery, abrogates lung Th2 responses and downregulates the expres sion of endothelial Pselectin.
Recent human studies have demonstrated that VEGF and VEGFRs are highly expressed in the lungs, BAL, and sputum of asthmatic subjects and that their levels correlate with disease severity (Hoshino et al., 2001b; Redington et al., 2001; Simcock et al., 2007; Tuder and Yun, 2008; Asosingh and Erzurum, 2009) . In experimental models, the overexpression of VEGF induced Th2 inflammation, and VEGF blockade inhibited aeroaller geninduced inflammation . However, de spite the abundance of evidence supporting the role of VEGF in asthma, the mechanism of this VEGF effect has not been adequately studied, and the clinical use of VEGF blockers in this disorder has never been realized. Our study defines the VEGF-miR1-Mpl axis in Th2 inflammation and suggests that this axis is also active in human asthma. By so doing, they introduce a novel VEGFdriven pathway that can be targeted to control Th2 and asthmalike responses.
Several studies have addressed the identities and effects of miRNAs involved in VEGFinduced angiogenesis (Fish et al., 2008; Suárez et al., 2008; Wang et al., 2008; Bonauer et al., 2009; Nicoli et al., 2010) . However, the roles of miRNAs in VEGFinduced inflammation and the mechanistic details of this contribution have never been investigated. Our experiments address these deficiencies. The downregulation of endothelial miR1 by VEGF, IL13, and allergeninduced inflammation and the ability of miR1 antagonists to overcome the effects of VEGFR blockade on Th2 inflammation establish the existence of a robust miR1 pathway downstream of VEGF in the lung. The direct targeting of the Mpl 3 UTR by miR1 and the demonstration that Mpl knockdown inhibits eosinophilic in flammation, mucus metaplasia, Th2 cytokine production, that coimmunoprecipitated with Ago2 (Ago2-IP) were measured by real-time qRT-PCR and normalized to the values for the scrambled control. The ratios represent miR-1-dependent RISC recruitment and are expressed as 2 Ct (data from three experiments; n = 4 in each group; values were compared by oneway ANOVA and corrected for multiple comparisons: *, P < 0.0002). (d) Relative concentration of each candidate mRNA in the Ago-IP fraction was divided by its relative concentration in the total cellular RNA (input fraction), and presented as 2 Ct (RISC enrichment analysis). Values for miR-1 were compared with those for scr-miR-1 (two experiments; n = 4 each group; *, P < 0.0005). (e and f) IL-13 expression was induced in IL-13 transgenic mice, and intranasal miR-1 was delivered as described in Fig. 4 c. RISC enrichment for miR-1 (*, P = 0.011) and its putative target genes (* and **, P < 0.03) were analyzed in whole lung lysates after Ago2-IP as described in c (two experiments; n = 3 per group). (g) Full-length Mpl 3 UTR was cloned downstream from the firefly luciferase gene. This vector was cotransfected with a control Renilla luciferase vector and miR-1 or scr-miR-1, and relative luciferase activity (firefly luciferase/Renilla luciferase expression) was measured with a luminometer (three experiments; n = 5 each group; *, P < 0.0001). (h) A 56-nt fragment of Mpl 3 UTR containing the miR-1 binding site with (Mut) or without (WT) compensatory mutations was cloned downstream of the firefly luciferase gene, and relative luciferase activity was measured as described in g (two experiments; n = 4 each; *, P < 0.005). Red letters indicate mutations in scr-miR-1, and green letters indicate compensatory mutations in Mpl 3 UTR. (i) MLECs were transfected with firefly luciferase-Mpl3 UTR (reporter construct) and Renilla luciferase vectors and stimulated with 100 ng/ml VEGF with or without 1 µM SU5416 (three experiments; n = 3 or more in each group; VEGF group was compared with the other two groups: *, P < 0.05). (a) C57BL/6 mice were sensitized to and challenged with OVA and received SU5416 (or vehicle) the day before the first challenge and every day afterward. Whole lung lysates from these mice were blotted with anti-Mpl or --actin antibodies. The top panel shows a representative Western blot, and the bottom panel shows the quantification based on densitometry (three experiments; n = 3 or more replicates in each; OVA-challenged groups were compared statistically: *, P < 0.05). (b) C57BL/6 mice were sensitized and challenged with OVA and received intranasal miR-1 as described in Fig. 3 . Whole lung lysates were blotted as described in a. The top panels show representative gels, and the bottom panel shows quantification based on densitometry (two experiments; n = 4 in each; *, all groups were compared with PBS-challenged mice; **, miR-1-treated mice were compared with scr-miR-1 and vehicle [OVA] groups: both * and **, P < 0.03). (c) Expression of Mpl in the lung endothelial cells from these mice was measured by real-time qRT-PCR (values normalized to those in PBS-challenged mice and presented as 2 Ct ; graphs represent two experiments; n = 4 or more in each group; *, P < 0.03). (d) C57BL/6 mice were sensitized and challenged with OVA and received SU5416 and miR-1 antagomir as described in Fig. 4 a. Whole lung lysates were blotted as described in a. The left panels show representative gels with three replicates in each group. The graph on the right shows quantification based on densitometry (two experiments; n = 4 or more in each group; OVA groups were compared by one-way ANOVA and multiple comparisons: *, P < 0.0001; three of the statistically significant comparisons are shown with horizontal bars). Error bars represent mean ± SEM. directly targeted by miR1, i.e., are recruited to RISC by miR1. We used two RISC recruitment assays to analyze the selective recruitment of a gene to the RISC in the presence of miR1 compared with its scrambled control (Fig. 5 c) and more specifically show selective enrichment of this gene in inhibited in the presence of miR1, and contain an miR1-responsive element in their 3 UTR (Fig. 5 a) . This method has been previously used to screen and identify miRNA tar gets (Lim et al., 2005; Ziegelbauer et al., 2009 ). Second, we used Ago2 immunoprecipitation to identify mRNAs that are (a-c) C57BL/6 mice were sensitized and challenged with OVA as described in Fig. 2 c and received intranasal Mpl siRNA or scrambled control (scr-ctrl) the day before the first challenge and every day afterward. (a) Lung sections were stained with H&E (top) for peribronchial inflammation and PAS (bottom) for mucus metaplasia (dark red) in the large airways. Bars, 50 µm. (b) BALs were collected from these mice and analyzed for eosinophilia (H&E stain of cytospin preps, top), IL-13, and IL-5 (ELISA, middle and bottom; three experiments; n = 4 or more in each group; OVA-challenged Mplsi-treated mice were compared with the OVA + scrambled control and vehicle [OVA] groups: for all comparisons *, P < 0.05). (c) Levels of MUC5AC in the BALs of these mice were measured by slot blot hybridization and normalized to the values in the PBS-challenged control group (graphs represent two experiments; n = 5 in each group; *, P < 0.001). (d and e) IL-13 expression was induced in IL-13 transgenic mice as described in Fig. 2 a, and intranasal Mpl siRNA or scr-ctrl was delivered on the day before starting the induction and every other day afterward. After 7 d, BALs were collected, and eosinophilia and MUC5AC expression was determined as described in Fig. 3 (b and e, respectively; values were normalized to the levels in the WT group; graphs represent data from two experiments; n = 3 or more in each group; for both *, P < 0.04). Error bars represent mean ± SEM. Figure 8 . The effect of the miR-1-Mpl axis on lung P-selectin. (a) MLECs were transfected with miR-1 and stimulated with VEGF, and extracted RNA was hybridized to an mRNA microarray as described in Fig. 5 a. Heat map shows the expression levels of various adhesion molecules under the four experimental conditions (the dataset was normalized and median centered; Icam1 and 2, intercellular adhesion molecule 1 and 2; Madcam1, mucosal vascular adressin cell adhesion molecule 1; Vcam1, vascular cell adhesion molecule 1; SELPLG, P-selectin glycoprotein ligand-1; the bar shows the color scale used in the administration of miR1 decreases the levels of Mpl and Pselectin, eosinophilic inflammation, mucus metaplasia, Th2 cytokine elaboration, eotaxin production, and AHR. These observations suggest that the Th2 inhibitory effects of miR1 or Mpl siRNA are mediated, at least in part, by the ability of these interventions to alter the adhesion molecule reper toire of the endothelium and, in turn, the entry of T cells and or eosinophils into the lung. Our demonstration that the accumulation of CD4 + T cells was decreased while levels of antigenspecific IgE were not altered by miR1 further supports this concept. The inhibitory effect of miR1 on the antigenindependent, eosinophilrich inflammatory response in IL13 transgenic mice further supports the concept that miR1 is not altering T cell sensitization or Th2 skewing.
The idea that endothelial events are critical regulators of Th2 inflammation is in accord with a sizable literature that has demonstrated that Pselectin plays an important role in recruiting T cells and eosinophils to the lung (Broide et al., 1998a,b; Symon et al., 1994; Lukacs et al., 2002; Stephens and Chaplin, 2002; Larbi et al., 2003; Ulfman et al., 2003; Banerjee, 2011) . Antigensensitized and challenged Pselectin-null mice fail to develop airway hyperreactivity or airway eosinophilia, whereas the levels of IgE in their serum are comparable with their WT littermate controls (Lukacs et al., 2002) . Asthmatic endothelial Pselectin can also directly activate eosinophil at tachment to the endothelium (Johansson and Mosher, 2011) . Eosinophils are required for and can significantly augment the severity of the allergeninduced inflammation by secret ing Th2 cytokines (Rosenberg et al., 2007) , activating and re cruiting T cells (MacKenzie et al., 2001; Mattes et al., 2002; Jacobsen et al., 2008; Walsh et al., 2008) , and modulating den dritic cell responses (Jacobsen et al., 2008) . Additional studies will be required to further define the mechanisms that the VEGF-miR1-Mpl-Pselectin pathway uses to regulate pul monary Th2 responses.
It is often crucial to investigate whether the pathways dis covered in animal models are actually operative in human cells and tissues. Because the Mpl miR1-responsive element in human differs from that in mice, this investigation is of even higher importance. To address this issue, we undertook experiments using primary human endothelial cells. These the Ago2IP fraction compared with the cytoplasmic fraction (Fig. 5 d) . Both of these assays have been widely used to de tect the direct targeting of genes by miRNAs (Liu et al., 2004; Karginov et al., 2007; Hendrickson et al., 2008; Fabian et al., 2009; Fasanaro et al., 2009; Challagundla et al., 2011; Thomson et al., 2011; Riley et al., 2012) . Third, we showed direct base pairing between miR1 and target gene 3 UTR by luciferase assay (Fig. 5 e) and mutational analysis (Fig. 5 f ) . Lastly, we confirmed the biological validity of this targeting by defining the effects of VEGF, miR1, and an miR1 antagomir on target expression (Figs. 5 d and 6 ). These experiments demonstrated that Mpl is the direct target of VEGF-miR1 axis in Th2 inflammation.
Mpl, the receptor for thrombopoietin, is known for its roles in megakaryopoiesis and hematopoietic stem cell differ entiation (Chou and Mulloy, 2011) . It is expressed on endo thelial cells and progenitors (Cardier and Dempsey, 1998; Amano et al., 2005; Jin et al., 2006; Eguchi et al., 2008) and affects the accumulation of plasma cells in bone marrow and the differentiation of mast cells (Migliaccio et al., 2007; Winter et al., 2010) . However, a direct proinflammatory role for Mpl has not been previously appreciated. Our study provides new insights into the biology of Mpl by demonstrating that Mpl plays an essential role in Th2 inflammation and endothelial Pselectin expression.
Pselectin is one of the main adhesion molecules expressed on the surface of the lung endothelium (Broide et al., 1998a,b) , and it is known that Mpl induces expression of Pselectin in platelets (Tibbles et al., 2002) . Human studies have also shown a close correlation between the levels of VEGF and cellular adhesion molecules such as ICAM1, VCAM1, and E, L, and Pselectins (AzimiNezhad et al., 2013) and that VEGF induces the expression of VCAM1 and Eselectin and pro motes the adhesion of leukocyte to the endothelium (Ismail et al., 2012) . The present study adds to our knowledge in this area by demonstrating that in Th2 inflammation, endothelial Pselectin expression is a component of the VEGF-miR1 pathway that is controlled through Mpl modulation. Specifi cally, they demonstrate that endothelial miR1 is inhibited by VEGF, leading to increased Mpl and Pselectin expression at sites of Th2 inflammation. They also demonstrate that the heat map; values are in log base). (b) C57BL/6 mice were sensitized and challenged with OVA and received miR-1 or scr-miR-1 as described in Fig. 3 . Whole lung lysates from these mice were blotted with anti-P-selectin and --actin antibodies. The top panel shows a representative blot of these lungs, and the graph shows quantification based on densitometry (data from two experiments; n ≥ 4 in each; *, all groups were compared with PBS-challenged mice; **, miR-1-treated mice were compared with the scr-miR-1 and vehicle [OVA] groups; both * and **, P < 0.04). (c) Representative images of lungs from mice treated as described in b and stained with anti-P-selectin antibody. (d) P-selectin expression was measured by real-time qRT-PCR in lung endothelial cells isolated from these mice (levels in OVA-challenged mice were normalized to PBS controls and presented as 2 Ct ; n = 4 or more in each group; *, P < 0.03). (e) MLECs were transfected with Mpl siRNA or scrambled control (scr-ctrl). The levels of P-selectin/GAPDH mRNA were measured by real-time qRT-PCR, normalized to the scrambled control, and expressed as 2 Ct (two experiments; n = 3 or more; *, P < 0.05). (f) C57BL/6 mice were sensitized and challenged with OVA and treated with Mpl siRNA or scr-ctrl as described in Fig. 7 a. Whole lung lysates from these mice were blotted as described in b. The top panel shows a representative gel, and the bottom panel shows quantification based on densitometry (two experiments; n = 4 or more in each group; *, all groups were compared with PBS-challenged mice; **, miR-1-treated mice were compared with the scr-ctrl and vehicle [OVA] groups; both * and **, P < 0.01). (g) P-selectin expression was measured by real-time qRT-PCR in lung endothelial cells isolated from these mice (values from Mplsi-treated mice were normalized to those in scr-ctrl-treated group and expressed as 2 Ct ; graphs represent data from two experiments; n = 5 in each group; *, P < 0.05). (h) Representative images of lungs from these mice stained with anti-P-selectin antibody. Bars, 50 µm. Error bars represent mean ± SEM. >50% of repeating probes on the chip), the median value of the repeating probes were calculated, different values were averaged, and the differential ra tios were presented in log2 scale. The statistical significance was analyzed by Student's t test, and the differentials reported as significant if P < 0.01. Array data were deposited in the GEO database (accession no. GSE50644). miRNA and mRNA analysis by qRT-PCR. miRNA analyses were per formed by TaqMan realtime qRTPCR assay (Applied Biosystems) on a 7500 Fast RealTime PCR machine and according to the manufacturer's in structions. Based on Applied Biosystems' technical recommendation, sno202 was used as the internal control. In each set, the test sample was compared with a calibrator (WT control or PBS treatment) and expressed as relative expression or 2 Ct . mRNA analyses were performed using the SYBER Green realtime RTPCR kit and according to the manufacturer's instructions (Applied Bio systems) on a 7500 Fast RealTime PCR machine. When the concentrations of the extracted RNA were <5 ng/µl (e.g., after MACS [magneticactivated cell sorting] for endothelial cells on a single lung), the mRNA or miRNA of interest and the corresponding normalization gene were preamplified as de scribed previously (Tang et al., 2006) .
Isolation of endothelial cells from the mouse lung by MACS.
Endo thelial (CD31 + , CD45  or CD105 + , CD45  ) and hematopoietic (CD45 + ) cells were isolated using Miltenyi Biotec magnetic columns or Dynabead Tosyl-activated Dynabeads and Dynamag15 magnet (Invitrogen) and corre sponding antibodies from the same manufacturers and according to the in structions. In brief, lungs were harvested from mice, sliced to small pieces in PBS buffer on ice, and filtered through 70µm and then 40µm nylon meshes to make a single cell suspensate, and RBCs were lysed using SigmaAldrich RBC lysis buffer. Cells were then counted by hemocytometer before incuba tion with the antibodycoated magnetic beads. Magnetic labeling and separa tions were performed according to the instructions. Total lung cell suspensates were first depleted of CD45 + cells and then positively selected for CD31 + or experiments demonstrated that VEGF decreased the levels of miR1 in human cells. They also demonstrated that, despite the sequence differences, miR1 inhibits hMpl via interacting with its 3 UTR. When viewed in combination, these experi ments demonstrate that the VEGF-miR1-Mpl axis is opera tive in humans.
In summary, this study highlights a novel endothelial miRNA-based pathway that plays an important role in the genesis of Th2 and IL13-induced responses in the lung. Specifically, they demonstrate that VEGF contributes to Th2 inflammation by downregulating miR1 in the endothelium, thereby increasing the expression of Mpl and its downstream target, Pselectin. This in turn contributes to recruitment of activated T cells and eosinophils into the lung and subsequent eosinophilic inflammation, Th2 cytokine elaboration, mucus metaplasia, and AHR. Additional investigations of this path way, its relationship to other VEGF and miR1-mediated re sponses, and its roles in health and disease are warranted.
MATERIALS AND METHODS
Microarray analysis. miRNA profiling of the mouse lungs was performed through the microarray service of LC Sciences after harvesting the lungs and RNA extraction by mirVana RNA Isolation kit (Ambion). Lung RNA from lung epithelial VEGF transgenic mice and their WT litters were labeled with Cy5 and Cy3, respectively, and hybridized on a microarray that detected miRNA transcripts listed in Sanger miRBase Release 9.1. For the array analy sis, the signal values were derived by background subtraction and normaliza tion. For all the detectable and acceptable signals (i.e., signal intensity higher than 3× background, spot coefficient of variation <0.5, and signals from 
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increasing concentrations of methacholine aerosol (10-80 mg/ml) generated with an inline nebulizer and administered directly through the ventilator for 10 s. Mean airway resistance (R) measures were calculated at each methacho line concentration.
RISC analysis. The recruitment of miRNAs and mRNAs to RISC was analyzed by Ago2 coimmunoprecipitation as described previously (Vasudevan and Steitz, 2007) with modifications. MLECs were grown in 10cm plates and transfected with doublestranded miR1 as described above. 48 h after transfection, cells were collected by scraping in cold PBS, spun down (110 g for 10 min at 4°C), and resuspended in 250 µl of cold lysis buffer (10 mM Hepes, pH 7.0, 150 mM KCl, 2 mM MgCl 2 , 2 mM DTT, 10% glycerol, 0.05% NP40, and 1 mM PMSF). Part of this lysate was kept as "input frac tion," and the rest was immunoprecipitated with antiAgo2 antibody (EMD Millipore) and protein G beads (GE Healthcare). The beads were directly added to TRIzol after washing three times (wash buffer is made by adding tRNA to the lysis buffer to the final concentration of 100 µg/ml) and the RNA extracted with mirVana kit after one round of chloroform extraction. miRNA and siRNA. Mature miR1 mimic was made by hybridizing the following two RNA oligonucleotides: M1s, 5UGGAAUGUAAAGAA GUAUGUA3; M1as, 5CAUACUUCUUUACAUUCACUA3. The scrambled control was made by hybridizing the following: Deltas, 5UUGAGAGUGAAUAAGAAUGUA3; Deltaas, 5CAUUCUUAU UCACUCUCCCUA3. This control contains sequence scrambled at only six positions. miR1 antagomir and its scramble control were designed and synthesized by Regulus and contained the following sequences with phos phorothioate modification of the backbone: miR1 antagomir, 5UACA UACUUCUUUACAUUCCA3; scrambled control, 5CCUUCCC UGAAGGUUCCUCCUU3. Mpl siRNA, VEGFR2 siRNA, and scram bled controls were purchased from Invitrogen.
Cell culture. MLECs were isolated from mouse lungs as described previ ously (Zhang et al., 2006) . P2P6 cells were used for the experiments. MLE12 cells were purchased from ATCC, and PASMCs were a gift from P. Lee's lab oratory at Yale Pulmonary and Critical Care Department. MLECs were grown in DMEM/F12 (Invitrogen) supplemented with 20% FCS. MLE12s and PASMCs were grown in DMEM (Invitrogen) supplemented with 2% and 10% FCS, respectively. Cells were starved in 0.1-0.5% FCS supplemented medium for 24 h before the addition of VEGF. Cultured cells were lysed directly by adding TRIzol (Invitrogen) to the wells, and RNA was purified extracted by the mirVana isolation kit after a chloroform extraction. Su5416 was added to the medium to the final concentration of 1 µM.
Transfections were performed using Lipofectamine 2000 (Invitrogen) and OptiMEM reagents and according the protocol recommended by the manufacturer for DNA or siRNA transfection, respectively. The medium was changed the next day, starvation started on the second day, and VEGF was added to the medium on the third day after transfection.
Plasmids, cloning, and luciferase assays. Mpl 3 UTR was cloned into the multiple cloning site of PGL3MCS (PO98) that was a gift from K. Riley in J. Steitz's laboratory (Yale University School of Medicine, New Haven, CT). This plasmid was constructed by cloning a fragment contain ing BglII-EcoRI-EcoRV-NdeI-PstI-SpeI-XhoI digestion sites into the Xba1 site of the PGL3 vector from Promega. In brief, mouse Mpl 3 UTR was amplified from mouse total genomic DNA (Promega) using the two primers F, 5GCAGCAGAGATCTAGGCAGTCCCCATG3; and R, 5TTCAGAGAATTCTTATTGGAGGTCTGCCAC3, which added a BglII and an EcoR1 site to the ends of the fragment, respectively. This PCR fragment was gel purified and cloned into PGEMTeasy (Promega), cut with BglII and EcoRI, and cloned into the corresponding sites in PGL3MCS. The miR1-binding site from the Mpl 3 UTR was constructed by hy bridizing the two DNA oligonucleotides F, 5GATCTAGTCCCCATGCT ACTGCAGACCTATACATTCCTACACACTACCTTATCCAG3; and R, CD105 + cells. The enrichment and purity of the endothelial cells were checked by FACS analysis of the selected cells and qRTPCR for VCAM on the RNAs extracted from the whole lung cells, CD45 + , CD45  /CD31 + , and CD45  /CD31 + cells.
Allergen sensitization and challenge. Sensitization and challenge with OVA was performed as described previously (Lee et al., 2009 ). In brief, C57BL/6 mice were sensitized to a mixture of OVA and Alum (Imject; SigmaAldrich) by i.p. injection, boosted with a second injection after 1 wk, and challenged with aerosolized OVA for 3 d, 3 wk after the initial sensitiza tion. Mice were injected i.p. with 20 µg/g SU5416 (dissolved in DMSO; SigmaAldrich) or given intranasal miR1 or Mpl siRNA (synthesized by Integrated DNA Technologies) the night before the first challenge and every night after the challenge afterward. In all of the experiments involving Su5416, the control mice were injected with DMSO i.p. HDM allergy was induced by i.p. injection of a mixture of HDM (Greer Labs; 1 µg DerP1 per mouse) and alum (Imject; SigmaAldrich; 3 mg per mouse) on day 0 (sensitization), followed by a boost dose of the same mixture i.p. on day 7 and antigenic challenge with intranasal HDM (2 µg DerP1) on days 17-19 after sensitization. miRNA delivery was similar to above.
Transgenic mice and intranasal delivery. All animal experiments were performed under protocol #200907586 approved by the Yale Institutional and Animal Care and Use Committee. All of the mice used in this manuscript are on a C57BL/6 background, and the WT controls of the transgenic mice were their littermates. All of the transgenic animals have been crossed with WTs for more than six generations. The generation and phenotype of the CC10rtTAVEGF and CC10rtTA-IL13 transgenic mice in which ex pression of human VEGF 165 and mouse IL13, respectively, is under the con trol of an inducible promoter has been described previously (Zhu et al., 1999; Lee et al., 2004) . Mice were grown to 6-8 wk, and expression of the trans gene was induced by adding 1 g/liter doxycycline to their drinking water for 7-10 d. For intranasal delivery, mice were anesthetized by i.p. injection of 0.5-0.7 ml ketamine/xylazine. A total of 50 µl of doublestranded RNA (1 µg/µl) in siRNA hybridization buffer (Thermo Fisher Scientific) was ad ministered by placing the tip of the pipetter near each nostril and injecting 10-20 µl each time as described previously (Zhang et al., 2004) . BAL and lung tissue analyses. Cytokines in the BAL or lung lysates were measured using R&D Systems ELISA kits and according to the manufactur er's instructions. Mucus hypersecretion was assessed in the BAL by slot blot analysis with antibody against MUC5AC as described previously (Zheng et al., 2008) . For the general assessment of lung inflammation and mucus metaplasia, lung sections were stained with hematoxylin and eosin (H&E) and periodic acidSchiff (PAS), respectively. Eosinophils in the lung tissues were counted in the bronchovascular areas after staining the lung sections with Congo Red. Four or more typical areas were delineated in each sample, the surface area was measured by ImageJ (National Institutes of Health), and the number of the eosinophils was expressed as the mean cells/mm 2 . CD4 + T cells in the BAL were detected by FACS analysis as described before (Niu et al., 2007) . In brief, 1-5 × 10 5 cells were stained with CD4APC and CD11bPE (1:1,000 and 1:2,000; both from BD) in staining buffer (0.1% BSA and 0.05% NaN3 in PBS) for 20 min, washed three times, and fixed in 1% paraformaldehyde (in PBS) and kept at 4°C overnight before FACS analy sis or analyzed directly after staining. Sorting was performed on a FACSCali bur (BD), and the data were analyzed using FlowJo (version 9; Tree Star). CD11b marker was used to exclude alveolar macrophages.
Measurement of AHR.
Airway responses were measured by the forced os cillation technique using FlexiVent (SCIREQ). Mice were anesthetized with 70 mg/kg pentobarbital and 1.8 g/kg urethane followed by 0.5 mg/kg pan curonium bromide. A tracheostomy was performed and a 19gauge metal needle was inserted, and mice were ventilated with a tidal volume of 10 ml/kg at a frequency of 150 breaths/min and a positive endexpiratory pressure of 3 cm H 2 O. Each mouse was challenged with saline (0 mg/ml) followed by 5AATTCTGGATAAGGTAGTGTGTAGGAATGTATAGGTCTGCAG TAGCATGGGGACTA3, digesting the resulting doublestranded DNA with BglII and EcoRI, and cloning the digested fragment into PGL3MCS as described above. The fragment containing a mutated binding site correspond ing to the scrambled control RNA was constructed as above by hybridizing the following two oligonucleotides: F, 5GATCTAGTCCCCATGCT ACTGCTGACATACACTCTCATACACACTACCTTATCCAG3; and R, 5AATTCTGGATAAGGTAGTGTAGGAGAGTGTATGTCAGCA GTAGCATGGGGACTA3. PCMVRenilla luciferase was a gift from K. Riley in J. Steitz's laboratory. Luciferase activity in the MLE12 cells trans fected with the above vectors was measured by the DualGlo luciferase assay kit (Promega) according to the instructions.
HUVECs were purchased from the Keck facility at Yale University and maintained in M199, 20% FBS, and EGS (1:1,000; purchased from the Keck facility). hMpl 3 UTR plasmid was purchased from Genecopoeia (miRNA 3 UTR target clones). Luciferase assay on the cells transfected with this plasmid was performed using lucpair luciferase assay kit (Genecopoeia) re agents according to the manufacturer's instructions.
Western blot analysis. Lungs were lysed in RIPA lysis buffer (Thermo Fisher Scientific) with added protease inhibitor (Roche), and the proteins were separated on a 4-20% gradient Tris polyacrylamide gel, transferred at 100 V for 1 h at 4°C. The blots were then blocked with 5% nonfat dry milk in TBST and incubated with 1:1,000 primary antibody (antiTPOR/cMpl; EMD Millipore) overnight before adding the secondary antibody (anti-rabbit; Santa Cruz Biotechnology, Inc.) and Femto Supersignal reagent (Thermo Fisher Scientific) and exposing to film. mRNA expression arrays. Cellular RNA for the array was extracted using the mirVana kit according to the instructions. The isolated mRNA was sent to the Keck center at Yale for hybridization to Illumina arrays. The signal val ues were reported as mean of repeating probes. The heat maps for the mRNA expression array were generated using Cluster and Treeview software. The data were polished for the clustering by normalizing rows and columns and median centering the columns.
Gel densitometry. Densitometries were performed on TIFF images of ra diographical films exposed to Western or slot blots. We used National Insti tutes of Health ImageJ software analysis and assigned values to each lane by integrating the area under the curve.
Statistical analyses.
In all comparisons, the mean and standard error of the datasets were calculated and presented in the graphs using Excel 2007 (Microsoft). Unless otherwise specified, statistical significance was analyzed by Student's t test. ANOVA tests were performed using Prism software (GraphPad Software). All error bars represent SEM.
